Fig. 2
From: Evaluating the prognostic value of CD56 in pediatric acute myeloid leukemia
Kaplan–Meier analysis for risk factors of all enrolled patients. A The overall survival (OS) rate for patients in CD56 positive and CD56 negative group. B Event-free survival (EFS) rate for patients in CD56 positive and CD56 negative group. C: The OS rate in the group over 36 months. D The EFS rate in the group under 36 months. E The OS rate for patients in standard-intermediate risk group. F The EFS rate for patients in high risk group